Posterior fossa ependymoma

Summary

Posterior fossa ependymoma (MONDO:0850339) is a disease and 1 clinical trial. A subtype of anaplastic ependymoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	posterior fossa ependymoma
Mondo ID	MONDO:0850339
DOID	DOID:0080889
NCIT	C186443
UMLS	C5670542
MedGen	1811888
GARD	0026605
Is cancer (heuristic)	no

Disease family

This is a subtype of anaplastic ependymoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › ependymal tumor › anaplastic ependymoma › posterior fossa ependymoma

Related subtypes (2): adult anaplastic ependymoma, supratentorial ependymoma

Subtypes (2): posterior fossa group A ependymoma, posterior fossa group B ependymoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02774421	PHASE1	ACTIVE_NOT_RECRUITING	Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma